MSB 6.57% 99.5¢ mesoblast limited

Ann: Appendix 4C Quarterly Activity Report, page-6

  1. 15,601 Posts.
    lightbulb Created with Sketch. 5691
    CHF

    It doesn't look like Novartis are the only ones in CHF discussions based on this paragraph

    Based on the observed reduction in mortality and morbidity in this Phase 3 trial, Mesoblast intends to meet with the FDA to discuss a potential approval pathway. Concurrently, Mesoblast will also explore potential strategic initiatives with a number of global pharma companies who have existing interests in cardiovascular disease and/or major vascular complications of diabetes.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
99.5¢
Change
-0.070(6.57%)
Mkt cap ! $1.136B
Open High Low Value Volume
$1.04 $1.04 99.5¢ $3.980M 3.944M

Buyers (Bids)

No. Vol. Price($)
8 56239 99.5¢
 

Sellers (Offers)

Price($) Vol. No.
$1.00 103125 2
View Market Depth
Last trade - 16.10pm 04/09/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.